AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

Millions of women struggle with the discomfort and stress of urinary incontinence, and many turn to medications for help. Now ...

Following a needed reinvention that resulted from the pandemic, there is now a seismic shift taking place in the fitness ...

In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Hair care encompasses many practices, but they often call for high-quality products that cost mammoth sums. Though these ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

With time, basketball and the techniques used in training basketball players have changed. Here come (VR) – a technology that ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

大会第三天，“OA08新一代细胞毒性药物”口头报告专场公布了一项由中国医学科学院肿瘤医院孙燕院士、上海交通大学附属上海市胸科医院韩宝惠教授以及中国医学科学院肿瘤医院石远凯教授作为主要研究者开展的DUBLIN-3研究的成果。该研究是一项Plinabulin+多西他赛对比多西他赛治疗铂类化疗进展后晚期非小细胞肺癌（NSCLC）III期随机对照临床试验，并在WCLC报告同日于《柳叶刀》杂志子刊《柳叶刀· ...